Name | Number of supported studies | Average coverage | |
---|---|---|---|
glutamatergic neuron | 4 studies | 41% ± 13% | |
GABAergic neuron | 3 studies | 34% ± 8% | |
interneuron | 3 studies | 42% ± 18% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 4 studies | 29% ± 10% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
prostate | 84% | 455.14 | 207 / 245 | 87% | 8.20 | 436 / 502 |
brain | 85% | 844.93 | 2241 / 2642 | 62% | 9.17 | 438 / 705 |
pancreas | 53% | 147.80 | 175 / 328 | 89% | 16.05 | 158 / 178 |
stomach | 58% | 254.34 | 208 / 359 | 71% | 9.14 | 203 / 286 |
intestine | 46% | 160.65 | 440 / 966 | 80% | 13.28 | 422 / 527 |
adrenal gland | 47% | 168.79 | 121 / 258 | 65% | 109.91 | 150 / 230 |
ureter | 0% | 0 | 0 / 0 | 100% | 6.81 | 1 / 1 |
blood vessel | 96% | 5094.75 | 1286 / 1335 | 0% | 0 | 0 / 0 |
spleen | 95% | 887.67 | 230 / 241 | 0% | 0 | 0 / 0 |
uterus | 20% | 64.58 | 34 / 170 | 60% | 12.11 | 276 / 459 |
esophagus | 13% | 26.88 | 187 / 1445 | 63% | 10.56 | 116 / 183 |
ovary | 31% | 93.88 | 55 / 180 | 44% | 4.61 | 190 / 430 |
tonsil | 0% | 0 | 0 / 0 | 69% | 8.91 | 31 / 45 |
bladder | 19% | 37.62 | 4 / 21 | 45% | 6.50 | 228 / 504 |
skin | 27% | 58.66 | 482 / 1809 | 37% | 5.20 | 175 / 472 |
lung | 16% | 46.76 | 95 / 578 | 46% | 13.04 | 527 / 1155 |
kidney | 49% | 130.78 | 44 / 89 | 12% | 1.45 | 104 / 901 |
breast | 24% | 52.40 | 112 / 459 | 28% | 2.49 | 309 / 1118 |
liver | 1% | 1.77 | 2 / 226 | 44% | 5.15 | 179 / 406 |
adipose | 19% | 45.41 | 231 / 1204 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 19% | 1.34 | 15 / 80 |
thymus | 11% | 23.96 | 72 / 653 | 6% | 0.44 | 39 / 605 |
heart | 10% | 19.62 | 82 / 861 | 0% | 0 | 0 / 0 |
muscle | 5% | 12.17 | 41 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
peripheral blood | 0% | 0 | 0 / 929 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0097009 | Biological process | energy homeostasis |
GO_0072659 | Biological process | protein localization to plasma membrane |
GO_0007631 | Biological process | feeding behavior |
GO_0106070 | Biological process | regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathway |
GO_0106072 | Biological process | negative regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathway |
GO_0106071 | Biological process | positive regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathway |
GO_0006112 | Biological process | energy reserve metabolic process |
GO_1903077 | Biological process | negative regulation of protein localization to plasma membrane |
GO_0005886 | Cellular component | plasma membrane |
GO_0005789 | Cellular component | endoplasmic reticulum membrane |
GO_0005783 | Cellular component | endoplasmic reticulum |
GO_0070996 | Molecular function | type 1 melanocortin receptor binding |
GO_0031780 | Molecular function | corticotropin hormone receptor binding |
GO_0031781 | Molecular function | type 3 melanocortin receptor binding |
GO_0030545 | Molecular function | signaling receptor regulator activity |
GO_0031783 | Molecular function | type 5 melanocortin receptor binding |
GO_0042802 | Molecular function | identical protein binding |
GO_0031782 | Molecular function | type 4 melanocortin receptor binding |
GO_0005515 | Molecular function | protein binding |
Gene name | MRAP2 |
Protein name | Melanocortin-2 receptor accessory protein 2 (MC2R accessory protein 2) |
Synonyms | C6orf117 |
Description | FUNCTION: Modulator of melanocortin receptor 4 (MC4R), a receptor involved in energy homeostasis. Plays a central role in the control of energy homeostasis and body weight regulation by increasing ligand-sensitivity of MC4R and MC4R-mediated generation of cAMP (By similarity). May also act as a negative regulator of MC2R: competes with MRAP for binding to MC2R and impairs the binding of corticotropin (ACTH) to MC2R. May also regulate activity of other melanocortin receptors (MC1R, MC3R and MC5R); however, additional evidence is required in vivo. . |
Accessions | ENST00000257776.5 Q96G30 |